Probiotic lactobacilli isolated from kefir promote down-modulation of inflamatory lamina propria T cells from patients with active IBD

RENATA CURCIARELLO; KARINA EVA CANZIANI; ILEANA SALTO; EMANUEL BARBIERA ROMERO; ANDRÉS ROCCA; IVÁN DOLDÁN; EMMANUEL PETÓN; SANTIAGO BRAYER; ALICIA MARÍA SAMBUELLI; SILVINA GONCAVES; PABLO TIRADO; GUSTAVO J. CORREA; MARTÍN YANTORNO; LAURA GARBI; GUILLERMO HORACIO DOCENA; MARÍA DE LOS ÁNGELES SERRADELL; CECILIA ISABEL MUGLIA

Frontiers in Pharmacology

Frontiers Media

Lugar: Laussane; Año: 2021

Ulcerative colitis and Crohn´s disease,the two main forms of inflammatory bowel disease (IBD), are immunologically mediated disorders. Severaltherapies are focused on activatedT cells as key targets.AlthoughLactobacillus kefiri has shownanti-inflammatory effects in animal models, few studies were done using human mucosalT cells. The aim of this work was to investigate the immunomodulatory effectsof this bacterium on intestinal T cells from patients with active IBD.Mucosal biopsies and surgical samplesfrom IBD adult patients (n=19) or healthy donors (HC; n=5) were used. Lamina propriamononuclear cells were isolated by enzymatic tissue digestion, and entero-adhesiveEscherichia coli-specific lamina propria T cells (LPTC) were expanded.The immunomodulatory properties of L.kefiri CIDCA 8348 strain were evaluated on biopsies and onanti-CD3/CD28-activated LPTC. Secreted cytokines were quantified by ELISA, andcell proliferation and viability were assessed by flow cytometry.We found that L. kefiri reduced spontaneous release of IL-6 and IL-8 frominflamed biopsies ex vivo. ActivatedLPTC from IBD patients showed low proliferative rates and reduced secretion of TNF-α,IL-6, IFN-g andIL-13 in the presence of L. kefiri. Inaddition, L. kefiri induced anincreased frequency of CD4+FOXP3+ LPTC along with high levelsof IL-10.This is the first report showing animmunomodulatory effect of L. kefiriCIDCA 8348 on human intestinal cells from IBD patients. Understanding themechanisms of interaction between probiotics and immune mucosal cells may opennew avenues for treatment and prevention of IBD.